Figure 5 from Ancestrally Diverse Autologous Patient-Derived Organoid–Immune Cell Coculture Platform for Addressing Immunotherapeutic Outcome Disparities in High-Grade Endometrial Cancer

Read full text Summarise with VIRAT
Authors: Charlie Chung, Brian Yueh, Santhilal Subhash, Onur Eskiocak, Aaron Nizam, Marissa G. Viola, Pascal Belleau, Ariel Kredentser, Arisa Kapedani, Alexander Krasnitz, Ken Simon, Werner Meier
+3 more Marina Frimer, Gary L. Goldberg, Semir Beyaz
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Bispecific TCE constructs facilitate cancer–immune cell interactions. A, Quantification of EpCAM protein expression levels of the MMRd and MMRp PDO lines measured by flow cytometry. MFI, mean fluorescent intensity. B, Representative images of autologous coculture using the MMRd HGEC PDO line. Red and green fluorescence represent organoids and corresponding immune cells, respectively. Blue fluorescence represents active caspase 3 signals. Scale bar, 70 μm. C, Representative images of autologous cancer–immune cell coculture using the MMRp HGEC PDO line. Scale bar, 70 μm. D, Colocalization of the MMRd HGEC PDOs and immune cells at 7 hours of coculture period. E, Viability of the MMRd PDO in the coculture measured by colocalization coefficient between organoid and caspase-3 signals at 12 hours coculture period. F, Colocalization of the MMRp HGEC PDOs and immune cells at 42 hours of coculture period. G, Viability of the MMRd organoid in the coculture measured by colocalization coefficient between organoid and caspase-3 signals at 46 hours coculture period. Cas3, caspase-3. t test (A) and ordinary one-way ANOVA (D–G) were used to calculate statistical significance (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001).

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Immunotherapy and Immune Responses Endometrial and Cervical Cancer Treatments

Publication details

Publication date
25 March 2026
Language
EN